EDITAS MEDICINE, INC. Equity Securities, FV-NI, Realized Gain
EDITAS MEDICINE, INC. (EDIT) reported Equity Securities, FV-NI, Realized Gain of $16.37 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-22.
Discontinued › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiRealizedGain · last filed 2023-02-22
- EDITAS MEDICINE, INC. equity securities, fv-ni, realized gain for fiscal 2020 was $16.37M.
| Period end | Equity Securities, FV-NI, Realized Gain 1 month | Equity Securities, FV-NI, Realized Gain 12 month |
|---|---|---|
| 2020-12-31 | $16.37M 10-K · filed 2023-02-22 | |
| 2020-10-31 | $16.40M 10-K · filed 2023-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |